Over five years, relapsing-remitting multiple sclerosis patients in France taking Tysabri have adopted more at-home dosing, a review found.

The CAR T-cell therapy KYV-101 is safe, and showed preliminary signs of efficacy in patients with progressive forms of MS in two trials.

Scientists have discovered a new immunotherapy strategy that reduces cancer recurrence in mouse experimental models. The ...

Independent Data Safety Monitoring Board (DSMB) recommends that the study proceeds as designed based on 30-day data safety assessment of ...

The company's cancer cell therapy Carvykti, which it makes in partnership with Legend Biotech, brought in sales of $369 million, above estimates of $324 million. Quarterly sales of J&J's cancer drugs ...

Researchers have developed novel lymph-node-inspired hydrogels that significantly enhance the activation, gene expression, ...

INmune Bio partners with UK-based Catapult to enhance cell therapy manufacturing for the production of its cell therapies.

Additionally, improving CAR-T biological efficiency could reduce dosing needs, further cutting costs and expanding access.

INmune Bio (INMB) has partnered with the Cell and Gene Therapy Catapult to establish large-scale, commercial-ready manufacturing for its cell ...

Dr. Laura Finn brings new treatment options to Louisiana using genetically altered cells to treat blood cancer patients. Here ...

A freak accident changed Nick Kharufeh’s life. He thought his vision might be gone forever, but a breakthrough in Boston is giving patients new hope.